Dianthus Therapeutics (formerly known as Magenta Therapeutics) is a clinical-stage biotechnology company. It develops medicines in stem cell biology and drug development field. The company has the following programs: MGTA-145, Stem Cell Mobilization & Collection Program for cell transplant from both patients and donors; MGTA-117, Targeted Conditioning Program, which is designed to reduce the need for high-dose or high-intensity chemotherapy. Magenta Therapeutics also has a Conditioning Research Platform that seeks to identify and advance the next candidates that deplete stem cells and/or immune cells from a patient prior to transplant, or HSC-based gene therapy.